Rose, I attribute the rise and fall in weekly gv prescriptions to supply issues. Our lack of growth (on captain beers chart) started when gv hit the market. I am going to assume that our slow to flat growth has to do with formulary changes to accommodate gv. We need AHA/ACC guidelines update. We are considered a standard of care in Canada. CVD organizations in the US need to step up. My opinion. Sleven,
Market Data 
Markets 
AI
